A New Chapter Begins as Walgreens Boots Alliance Goes Private in Landmark Deal

The acquisition of Walgreens Boots Alliance by Sycamore Partners has been finalized, marking a significant turning point for the major pharmacy chain. On August 28, 2025, the company officially delisted from the NASDAQ exchange, concluding its public market chapter and transitioning into private ownership under the new control of the private equity firm. The transaction, valued at $10 billion, paves the way for a strategic overhaul.

Leadership and Ownership Shift

Concurrent with the ownership change, a new leadership team has been appointed. Mike Motz, the former chief of Staples, has been named the new Chief Executive Officer, succeeding Tim Wentworth who guided the company through its final two years as a public entity. John Lederer has assumed the role of Executive Chairman to lead the board.

In a strong show of faith in the company’s future, Stefano Pessina and his family have chosen to reinvest the entirety of their WBA holdings into the newly private enterprise.

Shareholders received a cash payment of $11.45 for each share they held. The deal also includes the potential for additional future payments of up to $3.00 per share, contingent on the successful divestiture of certain VillageMD assets.

Strategic Store Closures Precede Takeover

In response to mounting financial pressures, the company had already initiated a drastic restructuring plan prior to the acquisition. In October 2024, Walgreens announced an extensive “Footprint Optimization Program,” targeting the closure of roughly 1,200 underperforming stores over a three-year period. This plan includes shuttering 500 locations within fiscal year 2025 alone.

The closures are heavily concentrated in specific underperforming markets, including:
– 35 locations in California
– 28 locations in Massachusetts
– 20 locations in Colorado

Management projected that this aggressive optimization would have an immediate positive effect on adjusted earnings per share and free cash flow.

Should investors sell immediately? Or is it worth buying Walgreens?

Financial Pressures Catalyze Change

The decision to go private was precipitated by a severe financial downturn. The company’s stock plummeted approximately 65% in value throughout 2024. This decline was fueled by staggering net losses, which reached $8.6 billion for the year, following a $3.1 billion loss the previous year.

The fourth-quarter 2024 results underscored these challenges. While revenue saw a 6.0% increase to $37.5 billion, adjusted earnings per share fell sharply by 40.8% to $0.39, indicating intense pressure on profitability.

These struggles are emblematic of broader headwinds facing the retail pharmacy sector, including pricing pressure from Pharmacy Benefit Managers that control an estimated 80% of prescription volume, fierce competition from online retailers, and declining front-store sales.

Future Outlook Under Private Ownership

With the acquisition complete, Sycamore Partners will operate Walgreens Boots Alliance’s portfolio companies as separate, standalone entities. This includes the core Walgreens retail business, The Boots Group, Shields Health Solutions, CareCentrix, and VillageMD.

This new structure is designed to allow each business unit to sharpen its focus on core competencies and could facilitate future strategic transactions. Sycamore is expected to accelerate its search for buyers for certain healthcare assets, with VillageMD being a primary candidate for divestiture.

Operating away from the scrutiny of public markets grants Walgreens the flexibility to execute long-term restructuring plans without the constant pressure of quarterly earnings reports. The appointment of a seasoned operational leader like Mike Motz signals a renewed focus on cost management and efficiency.

The privatization of such a prominent industry player highlights the profound challenges traditional pharmacy chains face in an era defined by digital disruption and an rapidly evolving healthcare landscape.